Objective  To explore the application model and prospect of hospital health technology assessment (HB-HTA) in hospital drug selection by conducting HB-HTA of three glucagon-like pep-tide-1 receptor agonists (GLP-1RA) weekly preparations, including semaglutide, dulaglutide and loxenatide. To provide an evidence-based basis for the scientific adjustment of the supply catalogue of essential drugs in hospitals.

Methods  Using drug HB-HTA quick scoring system, a total of 11 di-mensions were evaluated for semaglutide, dulaglutide and loxenatide in terms of clinical treatment necessity, effectiveness, safety, economy, compliance, national essential drugs attribute properties, health care, quality level, packaging, pharmaceutical enterprises, market attributes, respectively. Re-sults  The total scores of semaglutide, dulaglutide and loxenatide were 65, 64 and 60, respectively, and all of them can safely and effectively control blood glucose and increase cardiovascular benefits, and the advantage of using once a week can improve compliance of patients and quality of life. However, the above three drugs have certain differences in packaging and market attribute, and can be selected according to the actual needs.

Conclusions  The HB-HTA can provide an evidence-based basis for hospital selection and rational application of three GLP-1RA weekly preparations, and provide ideas for the establishment of drug management decision support system based on HB-HTA.

1.国务院办公厅. 关于改革完善医疗卫生行业综合监管制度的指导意见[EB/OL]. (2018-08-03) [2022-10-09]. http://www.gov.cn/zhengce/content/2018-08/03/content_5311548.htm.

2.吕兰婷, 施文凯, 林夏, 等. 新医改背景下基于知证决策的医院卫生技术评估功能与机制[J]. 中国循证医学杂志, 2020, 20(3): 335-339. [Lyu LT, Shi WK, Lin X, et al. Mechanism of evidence-based hospital-based health technology assessment in the context of new medical reform[J]. Chinese Journal of Evidence-Based Medicine, 2020, 20(3): 335-339.] DOI: 10.7507/1672-2531.201906086.

3.吕兰婷, 施文凯, 林夏, 等. 我国开展医院卫生技术评估的路径与策略[J]. 中国卫生政策研究, 2019, 12(8): 74-81. [Lyu LT, Shi WK, Lin X, et al. The path and development strategy of introducing hospital-based health technology assessment into Chinese hospital management[J]. Chinese Journal of Health Policy, 2019, 12(8): 74-81.] DOI: 10.3969/j.issn.1674-2982.2019.08.012.

4.王庆, 张蓉. 医院卫生技术评估在药品管理中的应用现状与发展思路[J]. 中国药房, 2020, 31(7): 773-777. [Wang Q, Zhang R. Ap-plication and development of hospital-based health technology assessment in pharmaceutical management[J]. China Pharmacy, 2020, 31(7): 773-777.] DOI: 10.6039/j.issn.1001-0408.2020.07.02.

5.林夏, 白飞, 吕兰婷, 等. 中国医院技术评估试点成效及推进策略[J]. 中国循证医学杂志, 2020(1): 94-97. [Lin X, Bai F, Lyu LT, et al. Exploration and research on hospital-based technology assessment in China[J]. Chinese Journal of Evidence-Based Medicine, 2020(1): 94-97.] DOI: 10.7507/1672-2531.201906081.

6.International Diabetes Federation. IDF Diabetes Atlas, 10th edition[EB/OL]. (2021-12-06) [2022-09-04]. https://diabetesatlas.org/atlas/tenth-edition/.

7.中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.DOI: 10.3760/cma.j.cn115791-20210221-00095.

8.王庆, 刘丹, 王强, 等. 医院卫生技术评估在3种SGLT2抑制药遴选评价中的应用[J]. 药物流行病学杂志, 2021, 30(9): 579-585. [Wang Q, Liu D, Wang Q, et al. Application of hospital-based health technology assessment in the selection and evaluation of three SGLT2 inhibitors[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(9): 579-585.] DOI: 10.19960/j.cnki.issn1005-0698.2021.09.002.

9.国家卫生健康委. 健康中国行动(2019—2030年) [EB/OL]. (2019-07-15) [2022-10-09]. http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.

10.American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S111-S124. DOI: 10.2337/dc21-S009.

11.欧盟AdHop HTA项目组, 主编. 医院卫生技术评估: 手册与工具包[M]. 上海: 上海交通大学出版社, 2017: 301-306.

12.赵志刚, 董占军, 刘建平. 中国医疗机构药品评价与遴选快速指南[J]. 医药导报, 2020, 39(11): 1457-1465. [Zhao ZG, Dong ZJ, Liu JP. A quick guideline for drug evaluation and selection in Chinese medical institu-tions[J]. Herald of Medicine, 2020, 39(11): 1457-1465.] DOI: 10.3870/j.issn.1004-0781.2020.11.001.

13.杨金伟. 药品临床综合评价管理指南发布[N]. 健康报, 2021-07-29(001). DOI: 10.28415/n.cnki.njika.2021.003528.

14.国家卫生健康委员会疾病预防控制局, 国家基层糖尿病防治管理办公室, 中华医学会糖尿病学分会, 主编. 中国糖尿病健康管理规范(2020)[M]. 北京: 人民卫生出版社, 2020: 67-68.

15.国家基层糖尿病防治管理办公室, 中华医学会糖尿病学分会. 国家基层糖尿病防治管理手册(2019)[J]. 中华内科杂志, 2019, 58(10): 713-735. DOI: 10.3760/cma.j.issn.0578‐1426.2019.10.003.

16.纪立农. 胰高血糖素样肽1受体激动剂周制剂中国证据与专家指导建议[J]. 中国糖尿病杂志, 2022, 30(6): 405-411. [Ji LN. Chinese evidence and expert advice on the preparation of glucagon-like peptide 1 receptor agonist[J]. Chinese Journal of Diabetes, 2022, 30(6): 405-411.] DOI: 10.3969/j.issn.1006-6187.2022.06.002.

17.国家卫生健康委员会能力建设和继续教育中心. 糖尿病患者合并心血管疾病诊治专家共识[J]. 中华内科杂志, 2021, 60(5): 421-437. DOI: 10.3760/cma.j.cn112138-20201208-00999.

18.国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(1): 14-46. DOI: 10.3760/cma.j.cn115791-20201209-00707.

19.中国药学会医院药学专业委员会. 聚乙二醇洛塞那肽临床应用专家共识[J]. 中国医院药学杂志, 2021, 41(24): 2507-2513, 2540. DOI: 10.13286/j.1001-5213.2021.24.01.

20.中华医学会内分泌学分会, 中华医学会糖尿病学分会. 胰高糖素样肽-1(GLP-1)受体激动剂用于治疗2型糖尿病的临床专家共识[J]. 中华内科杂志, 2020, 59(11): 836-846. DOI: 10.3760/cma.j.cn112138-20200704-00646.

21.中华医学会糖尿病学分会, 中华医学会内分泌学分会. 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华糖尿病杂志, 2020, 12(6): 369-381. DOI: 10.3760/cma.j.cn115791-20200419-00233.

22.葛均波, 霍勇, 高秀芳, 等. 改善心血管和肾脏结局的新型抗高血糖药物临床应用中国专家建议[J]. 中国循环杂志, 2020, 35(3): 231-238. [Ge JB, Huo Y, Gao XF, et al. Expert consensus on the use of new an-ti-hyperglycemic agents to improve cardiovascular and renal outcomes[J]. Chinese Circulation Journal, 2020, 35(3): 231-238.] DOI: 10.3969/j.issn.1000-3614.2020.03.002.

23.中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南[J]. 中华心血管病杂志, 2020, 48(12): 1000-1038. DOI: 10.3760/cma.j.cn112148-20201009-00796.

24.纪立农, 邹大进, 洪天配, 等. GLP-1受体激动剂临床应用专家指导意见[J]. 中国糖尿病杂志, 2018, 26(5): 353-361. [Ji LN, Zou DJ, Hong TP, et al. Clinical application of GLP-1 receptor agonists[J]. Chinese Journal of Di-abetes, 2018, 26(5): 353-361.] DOI: 10.3969/j.issn.1006-6187.2018.05.001.

25.Mancini GBJ, O'Meara E, Zieroth S, et al. 2022 Canadian cardiovascular society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults[J]. Can J Cardiol, 2022, 38(8): 1153-1167. DOI: 10.1016/j.cjca.2022.04.029.

26.Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabe-tes management algorithm-2020 executive summary[J]. Endocr Pract, 2020, 26(1): 107-139. DOI: 10.4158/CS-2019-0472.

27.Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabe-tes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Associa-tion for the Study of Diabetes (EASD)[J]. Diabetologia, 2020, 63(2): 221-228. DOI: 10.1007/s00125-019-05039-w.

28.Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardio-vascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020, 41(2): 255-323. DOI: 10.1093/eurheartj/ehz486.

29.Kalra S, Das AK, Sahay RK, et al. Consensus recommendations on GLP-1 RA use in the management of type 2 diabetes mellitus: south Asian task force[J]. Diabetes Ther, 2019, 10(5): 1645-1717. DOI: 10.1007/s13300-019-0669-4

30.国家卫生健康委员会. 关于印发国家基本药物目录（2018年版）的通知[EB/OL]. (2018-10-25) [2022-10-09]. http://www.gov.cn/zhengce/zhengceku/2018-12/31/content_5435470.htm.

31.国家医疗保障局, 人力资源社会保障部. 关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2021年)》的通知[EB/OL]. (2021-12-03) [2022-10-09].  http://www.nhsa.gov.cn/art/2021/12/3/art_53_7435.html.

32.国家药品监督管理局. 糖尿病治疗药物聚乙二醇洛塞那肽注射液获批上市[EB/OL]. (2019-05-07) [2022-10-09]. https://www.nmpa.gov.cn/yaopin/ypjgdt/20190507162501893.html.

33.Michael C. 2022 Pharm Exec Top 50 Companies[EB/OL]. (2022-06-10) [2022-10-09]. https://www.pharmexec.com/view/2022-pharm-exec-top-50-companies.

34.健康界. 工信部2020年中国医药工业百强榜发布[EB/OL]. (2021-08-02) [2022-10-09]. https://www.cn-healthcare.com/articlewm/20210802/content-1248490.html.

35.搜狐网. 2021年中国医药研发产品线最佳工业企业榜单正式发布[EB/OL]. (2021-08-01) [2022-10-09]. https://www.sohu.com/a/480784495_121123832.

36.卫生部深化医药卫生体制改革领导小组办公室.卫生技术评估的国际经验及启示[EB/OL]. (2011-11-14) [2022-11-24]. http://www.nhc.gov.cn/tigs/s9663/201205/c3937ff783bd4094bbee8fe9f455c728.shtml.

37.吕兰婷, 傅金澜, 林夏, 等. 中国医院卫生技术评估的困境与出路[J]. 中国医院管理, 2019, 39(2): 7-10. [Lyu LT, Fu JL, Lin X, et al. Dilemma and outlet of hospital-based health technology assessment in China[J]. Chi-nese Hospital Management, 2019, 39(2): 7-10.] DOI: CNKI:SUN:YYGL.0.2019-02-007.

38.Federici MO, McQuillan J, Biricolti G, et al. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study[J]. Diabetes Ther, 2018, 9(2): 789-801. DOI: 10.1007/s13300-018-0396-2.

39.Mody R, Huang Q, Yu M, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States[J]. Diabetes Obes Metab, 2019, 21(4): 920-929. DOI: 10.1111/dom.13603.